Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 87 results for inflammatory bowel disease

  1. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  2. Inflammatory bowel disease

    All NICE products on inflammatory bowel disease. Includes any guidance, advice and quality standards.

  3. Leukapheresis for inflammatory bowel disease (HTG75)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

  4. Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)

    This guideline covers using colonoscopy to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn’s disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to prevent cancer and prolong life by offering advice on identifying early bowel cancer in adults most at risk.

  5. PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)

    NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .

  6. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

  7. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

  8. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  9. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  10. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

  11. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  12. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  13. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  14. Natural history of progression to colorectal cancer in people at increased risk:- What is the natural history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas?

    history of progression to colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas? Any explanatory...

  15. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).